Abstract
Mild cognitive impairment (MCI), and the amnestic subtype of MCI in particular, is the most recent concept used to describe the intermediary state between healthy aging and Alzheimers disease (AD). It is hoped that research focusing on MCI would yield markers for early identification of individuals with prodromal AD at such a pre-dementia stage when potential disease modifying therapies would be most efficacious. Magnetic resonance imaging (MRI) combined with various data analysis methods provides tools to investigate alterations in brain structure and function in vivo. Structurally, MCI is characterized by atrophy of the medial temporal lobe (MTL) structures such as the hippocampus and entorhinal cortex, and the amount of atrophy in MCI is intermediate between healthy aging and AD. Additionally, atrophy of the posteromedial cortices such as the posterior cingulum and precuneus as well as of the lateral temporal cortices has been reported. The pattern of atrophy appears to vary according to the subtype of MCI. Functional MRI studies in MCI, compared to healthy aging and AD, have demonstrated both increased and decreased MTL activity during encoding novel visually presented material. Differences in the MTL activation pattern in MCI subjects may relate to differences in the severity of cognitive decline. There is some evidence that increased MTL activity observed during encoding may be compensatory due to incipient atrophy in the MTL structures. The resting state (or, “default mode”) network, and the posteromedial cortical regions in particular, appear to malfunction in MCI. It is suggested that both altered MTL and posteromedial cortical function may be indicative of future cognitive decline from MCI to clinical AD.
Keywords: Alzheimer's disease, early detection, fMRI, medial temporal lobe, memory, volumetry, voxel-based morphometry
Current Alzheimer Research
Title: Structural and Functional MRI in Mild Cognitive Impairment
Volume: 6 Issue: 2
Author(s): Maija Pihlajamaki, Anne M. Jauhiainen and Hilkka Soininen
Affiliation:
Keywords: Alzheimer's disease, early detection, fMRI, medial temporal lobe, memory, volumetry, voxel-based morphometry
Abstract: Mild cognitive impairment (MCI), and the amnestic subtype of MCI in particular, is the most recent concept used to describe the intermediary state between healthy aging and Alzheimers disease (AD). It is hoped that research focusing on MCI would yield markers for early identification of individuals with prodromal AD at such a pre-dementia stage when potential disease modifying therapies would be most efficacious. Magnetic resonance imaging (MRI) combined with various data analysis methods provides tools to investigate alterations in brain structure and function in vivo. Structurally, MCI is characterized by atrophy of the medial temporal lobe (MTL) structures such as the hippocampus and entorhinal cortex, and the amount of atrophy in MCI is intermediate between healthy aging and AD. Additionally, atrophy of the posteromedial cortices such as the posterior cingulum and precuneus as well as of the lateral temporal cortices has been reported. The pattern of atrophy appears to vary according to the subtype of MCI. Functional MRI studies in MCI, compared to healthy aging and AD, have demonstrated both increased and decreased MTL activity during encoding novel visually presented material. Differences in the MTL activation pattern in MCI subjects may relate to differences in the severity of cognitive decline. There is some evidence that increased MTL activity observed during encoding may be compensatory due to incipient atrophy in the MTL structures. The resting state (or, “default mode”) network, and the posteromedial cortical regions in particular, appear to malfunction in MCI. It is suggested that both altered MTL and posteromedial cortical function may be indicative of future cognitive decline from MCI to clinical AD.
Export Options
About this article
Cite this article as:
Pihlajamaki Maija, Jauhiainen M. Anne and Soininen Hilkka, Structural and Functional MRI in Mild Cognitive Impairment, Current Alzheimer Research 2009; 6 (2) . https://dx.doi.org/10.2174/156720509787602898
DOI https://dx.doi.org/10.2174/156720509787602898 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Memory Enhancing Effect of Black Pepper in the AlCl3 Induced Neurotoxicity Mouse Model is Mediated Through Its Active Component Chavicine
Current Pharmaceutical Biotechnology Cannabinoids and Cardiovascular Disease: The Outlook for Clinical Treatments
Current Vascular Pharmacology Why Is Homocysteine Toxic for the Nervous and Immune Systems?
Current Aging Science Insulin and the Brain
Current Diabetes Reviews Generation of Alzheimer’s Disease Transgenic Zebrafish Expressing Human APP Mutation Under Control of Zebrafish appb Promotor
Current Alzheimer Research Clinical Herbal Interactions with Conventional Drugs: From Molecules to Maladies
Current Medicinal Chemistry Patents of Pentoxifylline Administration on Some Diseases and Chronic Wounds
Recent Patents on Regenerative Medicine Small-molecule Modulation of HDAC6 Activity: The Propitious Therapeutic Strategy to Vanquish Neurodegenerative Disorders
Current Medicinal Chemistry Synthesis and Biological Activity of New 2,3-dihydro-1H-cyclopenta[b]- quinoline Derivatives as Acetylcholinesterase Inhibitors
Letters in Drug Design & Discovery Recent Advances in MRI Based Volumetry and Morphometry for AD Diagnosis in Human
Current Medical Imaging Glycosyltransferase and Glypiation Inhibitors
Current Organic Chemistry The Role of Physical Exercise and Omega-3 Fatty Acids in Depressive Illness in the Elderly
Current Neuropharmacology Development of Effective Therapeutics Targeting the GABAA Receptor: Naturally Occurring Alternatives
Current Pharmaceutical Design Anti-Angiogenic Treatment for Exudative Age-Related Macular Degeneration: New Strategies are Underway
Current Angiogenesis (Discontinued) Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Genetically-mediated Grey and White Matter Alteration in Normal Elderly Individuals with the CLU-C Allele Gene
Current Alzheimer Research Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Therapeutic Approaches to Alzheimer’s Type of Dementia: A Focus on FGF21 Mediated Neuroprotection
Current Pharmaceutical Design Targeted Delivery for Neurodegenerative Disorders Using Gene Therapy Vectors: Gene Next Therapeutic Goals
Current Gene Therapy